Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab209912-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$109.90
|
|
|
Ab209912-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$509.90
|
|
|
Ab209912-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,399.90
|
|
|
Ab209912-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,299.90
|
|
Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated
| Product Name | Jackson Foundation patent anti-ERG (anti-ERG) - Primary antibody, specific to ERG, Human IgG1 |
|---|---|
| Synonyms | Avian erythroblastosis virus E-26 (v-ets) oncogene related antibody | D030036I24Rik antibody | Erg 3 antibody | Erg antibody | ERG/EWS fusion gene, included antibody | ERG/FUS fusion gene, included antibody | ERG/TMPSSR2 fusion gene, included antibody | E |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure. |
| Host species | Human |
| Specificity | ERG |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Jackson Foundation patent anti-ERG (anti-ERG) is a monoclonal IgG1 antibody (mAb) directed against the proto-oncogene ETS-related gene (ERG). It has the potential to treat prostate cancer, Ewing's sarcoma, acute myeloid leukemia, endothelial cancer, and colon cancer. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 150 kDa |
| Purification Method | Protein A purified |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Jackson Foundation patent anti-ERG (anti-ERG) (Ab209912) - ELISA
Immobilized Recombinant Human ERG protein at 2.0 μg/mL can bind Jackson Foundation patent anti-ERG (anti-ERG) (Ab209912) with the EC50 of 22.39 ng/mL.
Jackson Foundation patent anti-ERG (anti-ERG) (Ab209912) - SEC
The purity of Jackson Foundation patent anti-ERG (anti-ERG) (Ab209912) is more than 95% verified by HPLC.